Ashley Crisostomo
Family · Oxnard, CANPI 1356862791
Payments from drug & device makers
Across 151 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$754
- Novo Nordisk$573
- AstraZeneca$413
- Lilly USA, LLC$402
- Boehringer Ingelheim$183
- Bayer$176
- plus $934 from 22 others
What the payments were for
- Food & beverage$3,436100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $754 |
| Novo Nordisk | 27 | $573 |
| AstraZeneca | 20 | $413 |
| Lilly USA, LLC | 16 | $402 |
| Boehringer Ingelheim | 8 | $183 |
| Bayer | 8 | $176 |
| Amgen | 5 | $128 |
| Merck | 4 | $112 |
| Corcept Therapeutics | 4 | $95 |
| Pfizer | 4 | $77 |
| GSK | 3 | $66 |
| Dexcom, Inc. | 3 | $60 |
| Johnson & Johnson | 2 | $47 |
| Novartis | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 2 | $41 |
| Lundbeck LLC | 1 | $31 |
| Medtronic | 1 | $29 |
| Abbott | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Tolmar, Inc. | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $16 |
| Intra-sana Laboratories | 1 | $15 |
| Insmed, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
How this compares
$3,436 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 23 | $21,633 |
| MounjaroTirzepatide | 18 | $19,113 |
| JardianceEmpagliflozin | 22 | $19,012 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $17,514 |
| RybelsusSemaglutide | 13 | $16,798 |
| Levothyroxine Sodium | 73 | $1,365 |
| Atorvastatin Calcium | 128 | $1,254 |
| Rosuvastatin Calcium | 52 | $678 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $640 |
| Amlodipine Besylate | 53 | $449 |
| Losartan Potassium | 50 | $438 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 38 | $421 |
| Gabapentin | 39 | $376 |
| Escitalopram Oxalate | 22 | $347 |
| Hydroxyzine Hcl | 13 | $330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $573 | $38,43136 claims |
| Lilly USA, LLCMounjaro | $402 | $19,11318 claims |
| Boehringer IngelheimJardiance | $183 | $19,01222 claims |
| GSKTrelegy Ellipta | $66 | $17,51416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in Oxnard
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.